Publications by authors named "Stefano Papi"

Claim this Profile
P
Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
Manila Rubino, Giuseppe Danilo Di Stasio, Lisa Bodei, Stefano Papi, Paola Anna Rocca

Endocrine· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First Results of β-Radioguided Surgery in Small Intestine Neuroendocrine Tumors with Y-DOTATOC.
Emilio Bertani, Francesco Collamati, Marzia Colandrea, Riccardo Faccini, Nicola Fazio, Stefano Papi

Cancer Biother Radiopharm· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
State of the Art and Recent Developments of Radiopharmaceuticals for Pancreatic Neuroendocrine Tumors Imaging.
Angela Carollo, Stefano Papi, Chiara M Grana, Luigi Mansi, Marco Chinol

Curr Radiopharm· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lutetium-177 Labeled Peptides: The European Institute of Oncology Experience.
Angela Carollo, Stefano Papi, Marco Chinol

Curr Radiopharm· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Annapaola Mariniello, Lisa Bodei, Carmine Tinelli, Silvia Melania Baio, Laura Gilardi, Stefano Papi

Eur J Nucl Med Mol Imaging· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin).
Stefano Papi, Luigi Martano, Lucia Garaboldi, Annalisa Rossi, Marta Cremonesi

Nucl Med Biol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of patients paced in VDD mode for advanced atrioventricular block: a pilot study.
Paolo Busacca, Giuliano Gheller, Mauro Pupita, Giovanni Berzigotti, Carlo Alberto Generali, Stefano Papi

J Cardiovasc Med (Hagerstown)· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
Marta Cremonesi, Mahila Ferrari, Chiara Maria Grana, Anna Vanazzi, Mike Stabin, Stefano Papi

J Nucl Med· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas.
Pier F Ferrucci, Anna Vanazzi, Chiara M Grana, Marta Cremonesi, Mirco Bartolomei, Stefano Papi

Br J Haematol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intraoperative avidination for radionuclide therapy: a prospective new development to accelerate radiotherapy in breast cancer.
Giovanni Paganelli, Mahila Ferrari, Laura Ravasi, Marta Cremonesi, Concetta De Cicco, Stefano Papi

Clin Cancer Res· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).
Nicoletta Urbano, Stefano Papi, Mauro Ginanneschi, Rita De Santis, Silvia Pace

Eur J Nucl Med Mol Imaging· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Localization of avidin in superficial bladder cancer: a potentially new approach for radionuclide therapy.
Marco Chinol, Ottavio De Cobelli, Giuseppe Trifirò, Epifanio Scardino, Mirco Bartolomei, Stefano Papi

Eur Urol· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors.
Giuseppina Sabatino, Marco Chinol, Giovanni Paganelli, Stefano Papi, Mario Chelli, Anna Maria Papini

J Med Chem· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis